Short sellers have built one of the most extreme positions in the micro-cap biotech universe heading into GNPX's Q1 results today, and the borrow market confirms the pressure isn't easing.
Short interest has more than doubled in a month — up 117% — to reach 73.8% of the free float, an extraordinary level for any stock at any size. The lending market underscores how aggressive this positioning is: availability sits at 67%, a relatively tight reading that signals meaningful demand for borrows relative to the pool. Cost to borrow is running near 17%, having come off a peak above 21% in early April — expensive, but not at extremes, suggesting bears can still fund positions without prohibitive cost. The ORTEX short score is 72.4, placing the stock in the top decile of the universe for short-side pressure. Against all of this, the stock has lost 26% in the past month, falling to $0.85, though it clawed back 2.5% in yesterday's session.
The bull-versus-bear split here maps almost entirely onto pipeline risk. Genprex's Reqorsa gene therapy program — targeting non-small cell lung cancer — recently secured an Israel Patent Office grant covering combination use with PD-1 antibodies, which represents a genuine IP milestone for the company. Bulls lean on clinical differentiation and the scarcity value of a functional TUSC2-based therapy. Bears point to a company with a negative enterprise value, a Q1 EPS of -$0.64 (sharply improved from -$13.00 year-over-year, partly reflecting share count changes), and no revenue base — the fundamental profile that keeps institutional ownership near zero. Institutional holders total just 12 names, with Lincoln Park Capital the largest at 0.22% of shares, and recent insider activity has been exclusively on the sell side, with the CFO and Chief Level Officer both selling shares in February at $2.00 — well above today's price.
Past earnings reactions have been volatile but consistently negative on a five-day basis. After the November 2025 print, the stock fell 27.5% over five days. After March 2026, it dropped 20.3% over the same window. The sole exception was April 2026, where an initial 7.4% pop reversed into a 15.7% five-day loss. The pattern shows that any relief rallies have been short-lived.
Today's print is less a test of whether Genprex is growing — it plainly isn't yet — and more a test of whether the pipeline narrative holds enough weight to absorb the wall of short interest that has quietly built to one of the most elevated readings in the small-cap biotech space.
See the live data behind this article on ORTEX.
Open GNPX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
